The question I always ask with Phase 2 results is "If these results were replicated in a Phase 3 study would we obtain product approval?". The answer to this question for CHF and Disc repair is yes but the answer for t2d is no, not even close. In my original post I did concede that maybe a different approach may do the trick but you can bet that if Phase 2 had delivered a 0.7 reduction we would be looking down the barrel of another Phase 3 by now. I just don't think it's helpful to put an overly positive gloss on everything. It diminishes the real positives. I have to filter everything you and Vin say to look for the real substance.
MSB Price at posting:
$5.75 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)